Estuary Biotherapeutics is a pioneering biotechnology firm dedicated to eradicating Autosomal Dominant Polycystic Kidney Disease (ADPKD), the most prevalent inherited kidney disorder globally. ADPKD is a progressive, lifelong condition where cysts develop and enlarge in both kidneys, ultimately leading to organ failure. For individuals with rapidly progressing ADPKD, end-stage kidney disease (ESKD), necessitating dialysis or transplant, is an inevitable outcome within their lifetime. Estuary's mission is to move beyond merely slowing disease progression, aiming instead for the ultimate solution: halting or even reversing ADPKD.
The company's innovative strategy centres on treating ADPKD at its genetic root cause. They employ adeno-associated virus (AAV) gene therapy to introduce a healthy copy of the PKD2 gene or a functional region of the PKD1 gene. This counteracts the effects of the inherited gene mutation responsible for the disease. Preclinical studies have demonstrated that restoring polycystin, the protein produced by these genes, can lead to transformative disease resolution, impacting both structural and functional outcomes in affected kidneys.
A key differentiator for Estuary is its proprietary local delivery approach. This method is specifically designed to suit the unique biology and accessibility of target kidney cells, enabling direct and precise delivery of genetic medicines. By pioneering this novel delivery pathway, Estuary aims to circumvent common challenges that have hindered previous gene therapy programmes. Their pipeline includes EST-201, a full-length PKD2 gene-addition therapy, and EST-101 and EST-102, which deliver a PC1-derived functional region via the same AAV serotype. This shared delivery route, target cell type, and AAV capsid across programmes create significant leverage and efficiency in their clinical development strategy, allowing for broader application to other monogenic and common forms of kidney disease.